Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL

Summary

This study aims to evaluate the safety, efficacy and duration of response of anti-CD19 anti-CD20 Bispecific Chimeric Antigen Receptor (CAR) redirected autologous T-cells in patients with high risk, relapsed CD19+ and CD20+ haematological malignancies.

Timeline

Start

2021-03-01

Primary completion

2022-03-01

Completion

2023-03-01

Drugs

Indications